Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
12.97
+0.56 (4.51%)
Apr 27, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
485.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 205.07M |
| REGENXBIO | 170.44M |
| Ginkgo Bioworks Holdings | 170.16M |
| 4D Molecular Therapeutics | 85.21M |
| XOMA Royalty | 52.15M |
| Entrada Therapeutics | 25.42M |
| Prelude Therapeutics | 12.14M |
| Armata Pharmaceuticals | 4.90M |
CTNM News
- 6 weeks ago - Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Contineum Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 7 weeks ago - Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
- 4 months ago - Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
- 4 months ago - Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
- 5 months ago - Contineum Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference - Transcripts
- 5 months ago - Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - Business Wire